Search
Now showing items 1-10 of 30195
Estudos sobre liberação controlada e vetorização de drogas através de lipossomas
(2005-06-01)
The text highlights the state of research related with the application of liposomes in the control of drug delivery and drug target to infectious diseases. Liposomes have several pharmaceutical applications and this ...
Estudos sobre liberação controlada e vetorização de drogas através de lipossomas
(2005-06-01)
The text highlights the state of research related with the application of liposomes in the control of drug delivery and drug target to infectious diseases. Liposomes have several pharmaceutical applications and this ...
Neutrophil-Derived MMP-8 Drives AMPK-Dependent Matrix Destruction in Human Pulmonary Tuberculosis
(Public Library of Science, 2015)
Pulmonary cavities, the hallmark of tuberculosis (TB), are characterized by high mycobacterial load and perpetuate the spread of M. tuberculosis. The mechanism of matrix destruction resulting in cavitation is not well ...
Killing of Cryptosporidium sporozoites by Lactoferrin
(American Society of Tropical Medicine and Hygiene, 2017)
Intestinal infection caused by Cryptosporidium is a major contributor to diarrhea morbidity and mortality in young children around the world. Current treatments for children suffering from cryptosporidiosis are suboptimal. ...
The importance of drug repurposing in the field of antiepileptic drug development
(Springer, 2016)
Drug repurposing involves finding new therapeutic uses for existing drugs, including marketed, discontinued, shelved, and investigational drugs. The advantages of this strategy are many: reduced drug development timeline, ...
Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax
(Springer Nature, 2016)
Plasmodium vivax is a major public health burden, responsible for the majority of malaria infections outside Africa. We explored the impact of demographic history and selective pressures on the P. vivax genome by sequencing ...
The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
(Taylor and Francis Ltd, 2020)